Hobbs FDR. Antithrombotic Therapy: New drugs and management strategies - updated.
This recently updated App provides an overview of established and novel therapies for preventing and managing thromboembolic disorders. Authored by a leading expert in the field, this App will be an invaluable accessible resource for both primary and secondary care clinicians.
The App provides a background to thrombosis and haemostasis, defines the high-risk patient, and reviews the pharmacology of current antithrombotic agents including antiplatelet therapies, heparins, fondaparinux, recombinant hirudins and vitamin K antagonists. Further sections give a particular focus on the direct oral anticoagulants (DOACs) rivaroxaban, dabigatran, edoxaban and apixaban. Data (clinical trials and real world studies) and prescribing information are summarised for the DOACs in the settings of prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation and secondary prevention in acute coronary syndrome.
It includes sections on current guidelines for clinical management of thromboembolic disorders and particular implications for primary care, plus comments on the future of antithrombotic therapy with ongoing trials in secondary prevention in acute coronary syndrome and mechanical valve replacement.
The App also contains an interactive case study on the diagnosis and management of atrial fibrillation which includes use of the DOACs and other agents.
- add your own notes within the content;
- bookmark certain pages;
- case studies with tests;